Grid radiation may boost sarcoma treatment before surgery
NCT ID NCT06073067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a special radiation technique called GRID therapy given before standard radiation and surgery for people with soft tissue sarcoma in their arms or legs. The goal is to see if GRID can safely increase the radiation dose to the tumor without causing more wound problems after surgery. Twenty adults with high-risk sarcoma will receive one GRID treatment, then standard radiation, then surgery. Researchers will track wound complications and how much of the tumor is killed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GRID radiation therapy
What this could lead to
If successful, this could improve tumor shrinkage before surgery without increasing wound complications, potentially leading to better outcomes for sarcoma patients.
What could go wrong
This is a very small pilot study (20 people) with no control group, so results may not be generalizable. The main risk is wound complications after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina at Chapel Hill, Department of Radiation Oncology
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact